Isoniazid-resistant tuberculosis: A problem we can no longer ignore

PLoS Med. 2020 Jan 21;17(1):e1003023. doi: 10.1371/journal.pmed.1003023. eCollection 2020 Jan.

Authors

Giorgia Sulis^{1

2}, Madhukar Pai^{1

2

3}

Affiliations

¹ Department of Epidemiology, Biostatistics and Occupational Health, McGill University, Montreal, Quebec, Canada.
² McGill International TB Centre, McGill University, Montreal, Quebec, Canada.
³ Manipal McGill Program for Infectious Diseases, Manipal Centre for Infectious Diseases, Manipal Academy of Higher Education, Manipal, Karnataka, India.

Abstract

Giorgia Sulis and Madhukar Pai discuss the global distribution, and approaches to diagnosis and treatment, of isoniazid-resistant tuberculosis.

Publication types

Comment

MeSH terms

Antitubercular Agents
Cross-Sectional Studies
Genetic Profile
Humans
Isoniazid
Prevalence
Tuberculosis*
Tuberculosis, Multidrug-Resistant*

Substances

Antitubercular Agents
Isoniazid

Grants and funding

The authors received no specific funding for this work.